At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lu AG09222 for the Prevention of Migraine in Patients With Unsuccessful Prior Preventive Treatments
In Brief
A Phase 2 clinical trial evaluating Lu AG09222 and Placebo for Migraine. Completed, enrolled 237 participants across 28 sites in 6 countries.
Detailed Summary
Researchers are trying to learn whether a drug called Lu AG09222 can help prevent migraine headaches for people who have not been helped by other treatments that are used to prevent migraines. People who join this trial have tried 2 to 4 other medications to prevent their migraines, but these medications have not helped them. When the trial is over, researchers will use this information to find out if the number of migraine days decreased more for the participants who got either dose of Lu AG09222 than for the participants who got the placebo.
Study Details
Timeline
Interventions
Lu AG09222 will be administered per schedule specified in the arm.
Placebo matching to Lu AG09222 will be administered per schedule specified in the arm.